Tenet Healthcare Corporation (THC)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NYSE
Market Cap: $22.76B
Last updated: Nov 17, 2026 at 11:06 AM ET
Tenet Healthcare Corporation (THC) Stock Forecast
Analysts expect Tenet Healthcare (THC) to earn $22.71 per share in the fiscal year ending Dec 31, 2026, on revenue of $22.31B. Of 23 analysts, 19 rate the stock Buy or Strong Buy, 4 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 10 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 23 ratings average 1.96, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 83% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 5 | 21.7% |
| Buy | 14 | 60.9% |
| Hold | 4 | 17.4% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 23
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus falls 10.7% and revenue estimates rise 0.9%.
- Fiscal year ending Dec 31, 2026
- $22.71
- EPS consensus, revenue $22.31B
- Fiscal year ending Dec 31, 2027
- $20.29
- EPS consensus, revenue $22.50B
- Next report
- Feb 9, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $22.71 | $22.05 to $23.10 | 19 | $22.31B | $22.22B to $22.55B | 19 |
| Dec 31, 2027 | $20.29 | $17.92 to $23.21 | 20 | $22.50B | $22.06B to $23.36B | 18 |
Quarterly Estimates
The EPS consensus falls from $5.34 for the quarter ending Dec 31, 2026 to $4.53 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $5.34 | $4.38 to $6.39 | 22 | $5.72B | $5.49B to $6.08B | 20 |
| Mar 31, 2027 | $4.53 | $3.85 to $5.34 | 12 | $5.46B | $5.29B to $5.65B | 8 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 13 upward and 13 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 10 | 0 |
| Fiscal year ending Dec 31, 2027 | 3 | 8 |
| Quarter ending Mar 31, 2027 | 0 | 5 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 7.1% from $21.21.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $22.71 | $22.65 | $21.22 | $21.22 | $21.21 | +7.1% |
| Fiscal year ending Dec 31, 2027 | $20.29 | $20.37 | $21.08 | $21.08 | $20.83 | -2.6% |
| Quarter ending Mar 31, 2027 | $4.53 | $4.59 | $4.93 | $4.91 | $4.83 | -6.2% |
Frequently Asked Questions About THC
What is the THC stock forecast?
Consensus analyst estimates put Tenet Healthcare's EPS at $22.71 for the fiscal year ending Dec 31, 2026, on revenue of $22.31B. The consensus rating from 23 analysts is Buy.
How do analysts rate THC stock?
Of 23 analysts covering Tenet Healthcare, 5 rate it Strong Buy, 14 Buy, 4 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from THC next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $22.71, with estimates from $22.05 to $23.10 from 19 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $20.29, with estimates from $17.92 to $23.21 from 20 analysts.
What revenue do analysts expect from Tenet Healthcare next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $22.31B, with estimates from $22.22B to $22.55B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $22.50B, with estimates from $22.06B to $23.36B.
How many analysts cover THC?
23 analysts rate Tenet Healthcare stock, and 19 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
THC pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts